Experimental AATD drug trial halted early: what we know
NCT ID NCT06677307
First seen Dec 29, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This early-stage study tested a new drug, KRRO 110, in healthy volunteers and people with Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can damage the lungs and liver. The main goal was to check safety and how the drug moves through the body. The trial was terminated before completion, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AATD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New Zealand Clinical Research
Auckland, New Zealand
-
New Zealand Clinical Research
Christchurch, New Zealand
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
-
St. Vincent's Hospital Melbourne
Melbourne, Victoria, 3065, Australia
-
The Prince Charles Hospital
Brisbane, Queensland, 4032, Australia
Conditions
Explore the condition pages connected to this study.